Al-Shamahi Asma
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK.
IDrugs. 2010 Nov;13(11):756-8.
The Japan Biotech Forum, held in London, included topics covering new licensing developments in the Japanese pharma and biotech industries. This conference report highlights selected presentations on licensing opportunities from several Japanese companies, including CanBas, LivTech, REGiMMUNE, D Western Therapeutics Institute and Chiome Bioscience. Investigational drugs discussed include CBP-501 (CanBas), LIV-2008 (LivTech), RGI-2001 (REGiMMUNE), IVX-214 (D Western Therapeutics Institute/ Nippon Shinyaku) and anti-Sema 3A (Chiome Bioscience).
在伦敦举行的日本生物技术论坛涵盖了日本制药和生物技术行业新的许可开发等主题。本会议报告重点介绍了几家日本公司（包括CanBas、LivTech、REGiMMUNE、D Western治疗研究所和Chiome生物科学公司）关于许可机会的精选演讲。讨论的研究性药物包括CBP - 501（CanBas）、LIV - 2008（LivTech）、RGI - 2001（REGiMMUNE）、IVX - 214（D Western治疗研究所/日本新药）和抗Sema 3A（Chiome生物科学公司）。
